Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
Breast Cancer: Basic and Clinical Research · 2016-01 · 10 · BCBCR.S39615
DOI: 10.4137/bcbcr.s39615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer: Basic and Clinical Research, online erschienen am 28.06.2016. Verfasst von Chris Twelves und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Clinical Cancer Research, Leeds Institute of Cancer and Pathology and St James's Institute of Oncology, Leeds, UK. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Purpose and Methods Our secondary analyses compared survival with eribulin versus capecitabine in various patient subgroups from a phase 3, open-label, randomized study. Eligible women aged ≥18 years with advanced/metastatic breast cancer and ≤3 prior chemotherapies (≤2 for advanced/metastatic disease), including an anthracycline and taxane, were randomized 1:1 to intravenous eribulin mesylate 1.4 mg/m 2 on days 1 and 8 or twice-daily oral capecitabine 1250 mg/m 2 on days 1–14 (21-day cycles).
Results
In the intent-to-treat population (eribulin 554 and capecitabine 548), overall survival appeared longer with eribulin than capecitabine in various subgroups, including patients with human epidermal growth factor receptor 2-negative (15.9 versus 13.5 months, respectively), estrogen receptor-negative (14.4 versus 10.5 months, respectively), and triple-negative (14.4 versus 9.4 months, respectively) disease. Progression-free survival was similar between the treatment arms.
Conclusions
Patients with advanced/metastatic breast cancer and human epidermal growth factor receptor 2-, estrogen receptor-, or triple-negative disease may gain particular benefit from eribulin as first-, second-, and third-line chemotherapies. Trial Registration (Primary Study) This study reports the subgroup analyses of eribulin versus capecitabine from a phase 3, open-label, randomized study ( www.clinicaltrials.gov ; ClinicalTrials.gov identifier: NCT00337103).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Clinical Cancer Research, Leeds Institute of Cancer and Pathology and St James's Institute of Oncology, Leeds, UK.
- Medical Oncology Clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
- Vall D'Hebron University Institute of Oncology, Barcelona, Spain.; Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
- Department of Medicine, University of Montreal, Montreal, QC, Canada.
- Department of Oncology, Leeds Institute of Cancer and Pathology, and St James's Institute of Oncology, University of Leeds, Leeds, UK.
- Oncology PCU, Department of Clinical Development, Eisai Inc., Woodcliff Lake, NJ, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Twelves, C., Awada, A., Cortes, J., Yelle, L., Velikova, G., Olivo, M. S., Song, J., Dutcus, C. E., & Kaufman, P. A. (2016). Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research, 10, BCBCR.S39615. https://doi.org/10.4137/bcbcr.s39615
Vancouver
Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, et al. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research. 2016;10:BCBCR.S39615. doi:10.4137/bcbcr.s39615
BibTeX
@article{Twelves2016,
author = {Twelves, Chris and Awada, Ahmad and Cortes, Javier and Yelle, Louise and Velikova, Galina and Olivo, Martin S and Song, James and Dutcus, Corina E and Kaufman, Peter A},
title = {Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer},
journal = {Breast Cancer: Basic and Clinical Research},
year = {2016},
volume = {10},
pages = {BCBCR.S39615},
doi = {10.4137/bcbcr.s39615}
}
EUVIMED